WO2001085193A3 - Method for promoting neovascularization using a tweak agonist and an angiogenic factor - Google Patents

Method for promoting neovascularization using a tweak agonist and an angiogenic factor Download PDF

Info

Publication number
WO2001085193A3
WO2001085193A3 PCT/US2001/014545 US0114545W WO0185193A3 WO 2001085193 A3 WO2001085193 A3 WO 2001085193A3 US 0114545 W US0114545 W US 0114545W WO 0185193 A3 WO0185193 A3 WO 0185193A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiogenic factor
tweak agonist
promoting neovascularization
tweak
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/014545
Other languages
French (fr)
Other versions
WO2001085193A8 (en
WO2001085193A2 (en
Inventor
Aniela Jakubowski
Linda Burkly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01933062A priority Critical patent/EP1363657A2/en
Priority to CA002408228A priority patent/CA2408228A1/en
Priority to NZ522741A priority patent/NZ522741A/en
Priority to JP2001581846A priority patent/JP2004500844A/en
Priority to AU2001259519A priority patent/AU2001259519C1/en
Priority to US10/275,997 priority patent/US6943146B2/en
Application filed by Biogen Inc filed Critical Biogen Inc
Priority to AU5951901A priority patent/AU5951901A/en
Publication of WO2001085193A2 publication Critical patent/WO2001085193A2/en
Anticipated expiration legal-status Critical
Publication of WO2001085193A3 publication Critical patent/WO2001085193A3/en
Publication of WO2001085193A8 publication Critical patent/WO2001085193A8/en
Priority to US11/145,340 priority patent/US20060003932A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method for enhancing angiogenic activity to promote neovascularization comprising administering to a subject a formulation comprising a synergistically effective amount of a TWEAK agonist and an angiogenic factor.
PCT/US2001/014545 2000-05-08 2001-05-07 Method for promoting neovascularization using a tweak agonist and an angiogenic factor Ceased WO2001085193A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU5951901A AU5951901A (en) 2000-05-08 2001-05-07 Method for promoting neovascularization
CA002408228A CA2408228A1 (en) 2000-05-08 2001-05-07 Method for promoting neovascularization
NZ522741A NZ522741A (en) 2000-05-08 2001-05-07 Method for promoting neovascularization using a TWEAK agonist and an angiogenic factor, such as fibroblast growth factor and VEGF
JP2001581846A JP2004500844A (en) 2000-05-08 2001-05-07 Method for promoting neovascularization using a TWEAK agonist and an angiogenic factor
AU2001259519A AU2001259519C1 (en) 2000-05-08 2001-05-07 Method for promoting neovascularization
EP01933062A EP1363657A2 (en) 2000-05-08 2001-05-07 Method for promoting neovascularization using a tweak agonist and an angiogenic factor
US10/275,997 US6943146B2 (en) 2000-05-08 2001-05-07 Method for promoting neovascularization
US11/145,340 US20060003932A1 (en) 2000-05-08 2005-06-02 Method for promoting neovascularization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20273800P 2000-05-08 2000-05-08
US60/202,738 2000-05-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/145,340 Continuation US20060003932A1 (en) 2000-05-08 2005-06-02 Method for promoting neovascularization

Publications (3)

Publication Number Publication Date
WO2001085193A2 WO2001085193A2 (en) 2001-11-15
WO2001085193A3 true WO2001085193A3 (en) 2003-09-04
WO2001085193A8 WO2001085193A8 (en) 2003-12-24

Family

ID=22751060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/014545 Ceased WO2001085193A2 (en) 2000-05-08 2001-05-07 Method for promoting neovascularization using a tweak agonist and an angiogenic factor

Country Status (7)

Country Link
US (2) US6943146B2 (en)
EP (1) EP1363657A2 (en)
JP (1) JP2004500844A (en)
AU (2) AU2001259519C1 (en)
CA (1) CA2408228A1 (en)
NZ (1) NZ522741A (en)
WO (1) WO2001085193A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101000842B1 (en) 2002-04-09 2010-12-14 바이오겐 아이덱 엠에이 인코포레이티드 How to treat TVE-related conditions

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
EP1141027A1 (en) 1999-01-15 2001-10-10 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
EP2298333A3 (en) 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002009650A2 (en) 2000-07-31 2002-02-07 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
EP1648936B1 (en) 2003-07-24 2007-06-06 Amgen Inc. Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor
WO2006088890A2 (en) * 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
US20090124993A1 (en) * 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
JP5339901B2 (en) * 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment and evaluation of inflammatory injury
PL2460831T3 (en) 2005-05-27 2017-05-31 Biogen Ma Inc. Tweak binding antibodies
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9068004B2 (en) 2010-02-04 2015-06-30 University Of Louisville Research Foundation, Inc. TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
WO2012065003A2 (en) * 2010-11-11 2012-05-18 Microstem, Inc. Screening and culturing device and methods for the use thereof
EP2643028B1 (en) * 2010-11-26 2017-12-06 Stemlab SA Composition and method to improve the therapeutic effect of stem cells
CN107787202B (en) 2015-04-02 2024-03-22 哈特弗罗公司 Systems and methods for predicting perfusion defects from physiological, anatomical and patient characteristics
CN106046130B (en) * 2016-07-07 2017-12-12 胡国田 A kind of polypeptide and its application
CN107328943B (en) * 2017-07-28 2019-04-16 东曜药业有限公司 A kind of detection method and application of vascular endothelial growth factor biological activity
JP2024516548A (en) 2021-04-08 2024-04-16 ジョスリン ダイアビーティス センター インコーポレイテッド Methods for diagnosing and predicting renal dysfunction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035061A2 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US6544761B2 (en) * 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
AU708829B2 (en) 1994-12-13 1999-08-12 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
IL128407A (en) 1996-08-07 2007-07-24 Biogen Idec Inc Tumor necrosis factor related ligand
US5858991A (en) 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
WO1998055508A2 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
ATE393222T1 (en) 1997-09-18 2008-05-15 Genentech Inc DCR3 POLYPEPTIDE, A TNFR HOMOLOGUE
DE69840631D1 (en) 1997-10-10 2009-04-16 Genentech Inc APO-3 LIGAND
WO1999059614A1 (en) 1998-05-20 1999-11-25 Yale University Modulation of angiogenesis and wound healing
JP2002516082A (en) 1998-05-29 2002-06-04 インサイト・ファーマスーティカルズ・インコーポレイテッド Human transmembrane protein
KR100499600B1 (en) 1998-12-22 2005-07-07 제넨테크, 인크. Methods and Compositions for Inhibiting Neoplastic Cell Growth
EP1141027A1 (en) 1999-01-15 2001-10-10 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
ATE348108T1 (en) 1999-03-08 2007-01-15 Genentech Inc METHOD FOR DETECTING TUMORS
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
KR20050004240A (en) 1999-08-31 2005-01-12 제넨테크, 인크. Compositions and Methods for the Treatment of Tumor
EP2298333A3 (en) 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
EP1248645B1 (en) 2000-01-03 2007-04-18 Tr Associates, L.L.C. Novel chimeric proteins and their use
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
ATE358718T1 (en) 2000-02-25 2007-04-15 Immunex Corp INTEGRIN ANTAGONISTS
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
US20040047854A1 (en) 2001-07-27 2004-03-11 Black Roy A. Human disintegrin protein
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
EP1478740A2 (en) 2001-07-27 2004-11-24 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
US20040091473A1 (en) 2001-07-27 2004-05-13 Dubose Robert F. Metalloproteinase-disintegrin polypeptides and methods of making and use thereof
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
AU2003224950B2 (en) 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035061A2 (en) * 1997-02-12 1998-08-13 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. JAKUBOWSKI ET AL.: "TWEAK SYNERGIZES WITH BASIC FIBROBLAST GROWTH FACTOR TO INDUCE ENDOTHELIAL CELL PROLIFERATION, MIGRATION AND LUMEN MORPHOGENESIS.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 51, no. suppl. 1, June 2000 (2000-06-01), OXFORD, GB, pages 62, XP001053007 *
C.N. LYNCH ET AL.: "TWEAK INDUCES ANGIOGENESIS AND PROLIFERATION OF ENDOTHELIAL CELLS.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 13, 26 March 1999 (1999-03-26), BALTIMORE, MD, US, pages 8455 - 8459, XP002187977 *
See also references of EP1363657A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101000842B1 (en) 2002-04-09 2010-12-14 바이오겐 아이덱 엠에이 인코포레이티드 How to treat TVE-related conditions

Also Published As

Publication number Publication date
NZ522741A (en) 2005-06-24
EP1363657A2 (en) 2003-11-26
WO2001085193A8 (en) 2003-12-24
US20030211993A1 (en) 2003-11-13
CA2408228A1 (en) 2001-11-15
AU2001259519B2 (en) 2005-02-03
AU5951901A (en) 2001-11-20
WO2001085193A2 (en) 2001-11-15
AU2001259519C1 (en) 2005-09-22
JP2004500844A (en) 2004-01-15
US6943146B2 (en) 2005-09-13
US20060003932A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
WO2001085193A8 (en) Method for promoting neovascularization using a tweak agonist and an angiogenic factor
AU8206401A (en) Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
AU2001236457A1 (en) Compounds and compositions for delivering active agents
PL378927A1 (en) Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth
EP1337249A4 (en) Compositions and methods for administration of pharmacologically active compounds
IL152339A0 (en) Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
FI973828L (en) Compounds and compositions for delivering active ingredients
AU2001277543A1 (en) Synergistically active mixture which inhibits hair growth
HUP0401984A3 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
EE200300240A (en) Arylated furan and thiophenecarboxamide, a pharmaceutical formulation containing it and use of the compound in the preparation of a potassium channel blocker
ATE452640T1 (en) REMEDIES FOR DISEASES ASSOCIATED WITH BONE LOSS
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
AU1261501A (en) Compositions and methods for intranasal delivery of active agents to the brain
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO1998042322A3 (en) Antitussive compositions
AU2001288277A1 (en) Compounds and compositions for delivering active agents
AU1262501A (en) Compositions for transdermal and transmucosal administration of therapeutic agents
WO2001034172A3 (en) Methods and compositions for treating reward deficiency syndrome
WO2002100404A3 (en) Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
IL179378A0 (en) Method and formulation for transdermal delivery of immunologically active agents
WO2002064160A3 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
EE04811B1 (en) Substituted 3-phenyl-5-alkoxy-1,3,4-oxydiazol-2-one, its preparation and its use as a lipase inhibitor, and medicament containing it
WO2003015690A3 (en) Method for treating primary insomnia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2408228

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10275997

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001259519

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 522741

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001933062

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001933062

Country of ref document: EP

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE; PUBLISHED FIGURE DELETED

WWG Wipo information: grant in national office

Ref document number: 2001259519

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 522741

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 522741

Country of ref document: NZ